Prestige Wealth Management Group’s Outlook Therapeutics OTLK Stock Holding History
Bought
Maintained
Sold
Other funds holding OTLK
PA
HF
GWM
Prestige Wealth Management Group's OTLK Position: Q2 2026 in Review
Prestige Wealth Management Group held its Outlook Therapeutics (OTLK) position steady in Q2 2026 at 62 shares worth $99. The position accounts for ﹤0.01% of the portfolio, ranked #1095.
Prestige Wealth Management Group first reported a position in OTLK in Q1 2019 and has held it in 30 quarters since. The position peaked at $9K in Q1 2019. 69 funds tracked by Wall St. Rank hold OTLK as of Q2 2026.
- Prestige Wealth Management Group held 62 shares of Outlook Therapeutics worth $99 as of Q2 2026.
- Prestige Wealth Management Group left its Outlook Therapeutics share count unchanged in Q2 2026.
- Outlook Therapeutics made up ﹤0.01% of Prestige Wealth Management Group's portfolio in Q2 2026, its #1095 holding.
- Prestige Wealth Management Group first reported a position in Outlook Therapeutics in Q1 2019 and has held it in 30 quarters since.
- Prestige Wealth Management Group's Outlook Therapeutics position peaked at $9K in Q1 2019.
- 69 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2026.
Based on Prestige Wealth Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.